logo-loader
CannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics to research a cannabis-derived pain treatment for cats

The company has entered into a research services agreement Eurofins Animal Health Pty Ltd.

Photo of cat
The collaboration will seek to expand the development program for CPAT-01

CannPal Animal Therapeutics Ltd (ASX:CP1) will work with veterinary research organisation Eurofins Animal Health Pty Ltd to develop a cannabis-derived pain treatment for cats.

The two companies have entered into a research services agreement which will see Eurofins design and facilitate pilot studies in cats at its research facility in New South Wales.

READ: CannPal Animal Therapeutics achieves milestone in Phase 1A study

CannPal recently completed Phase 1A of a Pharmacokinetic and Safety Study for CPAT-01, the company’s lead drug candidate being developed as a pain control for dogs.

The promising safety profile has given management the confidence to expand the development program to include cats (CPAT-01C) as a pain control for felines.

CannPal’s founder and managing director Layton Mills said: “We’re delighted to announce a research collaboration with Eurofins to expand the development program of CPAT-01 into cats.

“We believe that there’s a significant unmet need for a feline pain treatment with a more desirable safety profile.”

 

The agreement will see Eurofins prepare and submit ethics applications for study clearance.

It will be responsible for fulfilling associated ethics reporting requirements and carrying out the animal’s phase of the research.

READ: Cannpal Animal Therapeutics Ltd working with CSIRO in developing cannabinoid treatments for animals

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used treatment for pain in cats, yet only two NSAID’s have been approved for use by the FDA in the USA.

None have been approved for long-term use due to potential side effects and toxicities.

Alternative solution to treat cats

CannPal hopes that CPAT-01C can offer an alternative solution to help treat pain in cats in a safe and ethical way.

Mills said: “I strongly feel that this opportunity can create added value for our shareholders.”

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

Eurofins supports animal health industry

Eurofins is a leader in food, environment and pharmaceutical products testing and in agroscience and veterinary research services that support the global animal health industry.

It conducts preclinical and clinical studies to GCP and GLP standards, compliant with regulatory requirements, and serve as an ideal partner to commence CannPal’s research on pain treatment for cats.

Technical activities involve the conduct of clinical field, pen and laboratory studies to determine the safety and efficacy of new products designed to improve animal health and welfare.

Quick facts: CannPal Animal Therapeutics Ltd

Price: $0.16

Market: ASX
Market Cap: $14.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 25/6/18

3 min read